MARKET

APVO

APVO

Aptevo
NASDAQ

Real-time Quotes | Nasdaq Last Sale

23.18
+0.26
+1.13%
Closed 16:00 05/17 EDT
OPEN
22.53
PREV CLOSE
22.92
HIGH
23.44
LOW
22.18
VOLUME
8.43K
TURNOVER
--
52 WEEK HIGH
60.00
52 WEEK LOW
4.619
MARKET CAP
103.14M
P/E (TTM)
-2.5284
1D
5D
1M
3M
1Y
5Y
American Eagle Completes Magnetotelluric Survey at its Golden Trend Property in the Cortez, Nevada; Publishes Interview with CEO Anthony Moreau and VP of Exploration Mark Bradley
American Eagle Gold Corp. (TSXV: AE) ("American Eagle" or the "Company") is pleased to announce that its contractor Zonge Engineering has completed a new Controlled Source Audio Magnetotelluric ("CSAMT") geophysical resistivity survey on the Company's flag...
CNW Group · 12h ago
Hemophilia Drugs Market Size 2021 | Is Expected to Progress at a CAGR of 6% and Reach USD 15,830 Million by the end of 2025
The global "hemophilia drugs market" is expected to gain from increasing cases of gene mutation. Fortune Business Insights recently published a report, titled "Hemophilia Drugs Market Size, Share and Global Trend By Disease Indication (Hemophilia A, B & C)...
GlobeNewswire · 15h ago
8-K: Aptevo Therapeutics Inc.
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT (EDGAR Online via COMTEX) -- Pursuant to Section 13 or 15(d)...
Edgar Online - (EDK = 8-Ks/S1/S-4) · 5d ago
APTEVO THERAPEUTICS INC. (NASDAQ:APVO) Files An 8-K Results of Operations and Financial Condition
May 11, 2021 (Market Exclusive via COMTEX) -- APTEVO THERAPEUTICS INC. (NASDAQ:APVO) Files An 8-K Results of Operations and Financial ConditionItem 2.02...
Market Exclusive · 6d ago
Aptevo Therapeutics Reports First Quarter 2021 Financial Results
Advances Phase 1/1b Study of APVO436 for Treatment of Acute Myeloid Leukemia and High-Grade Myelodysplastic Syndrome; Dosing in Cohort 10 OngoingSEATTLE, WA / ACCESSWIRE / May 11, 2021 / Aptevo Therapeutics Inc. ("Aptevo" or "the Company") (NASDAQ:APVO), a...
ACCESSWIRE · 6d ago
BRIEF-Aptevo Therapeutics Inc Says Qtrly Royalty Revenue Was $2.4 Million
reuters.com · 6d ago
Aptevo Therapeutics EPS misses by $0.12, misses on revenue
Aptevo Therapeutics (APVO): Q1 GAAP EPS of -$1.74 misses by $0.12.Revenue of $2.42M misses by $10.65M.Press Release
Seekingalpha · 6d ago
Double Barreled Antibodies Drug Market Growth, Latest Trend and Forecast 2021 - 2028 By Ameco Research
Comserve · 05/10 04:12
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of APVO. Analyze the recent business situations of Aptevo through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average APVO stock price target is 65.67 with a high estimate of 69.00 and a low estimate of 64.00.
EPS
Institutional Holdings
Institutions: 69
Institutional Holdings: 5.64M
% Owned: 126.76%
Shares Outstanding: 4.45M
TypeInstitutionsShares
Increased
6
139.25K
New
22
2.38M
Decreased
5
126.62K
Sold Out
5
134.19K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
No Data
No Data
About APVO
Aptevo Therapeutics Inc. is a biotechnology company. The Company is focused on oncology and hematology therapeutics. The Company is engaged in the discovery, development, commercialization and sale of oncology and hematology therapeutics. The Company's technology is the ADAPTIR (modular protein technology) platform. The Company has approximately four products in the areas of hematology and infectious diseases, as well as various investigational-stage product candidates in immuno-oncology. The Company's investigational-stage product candidates include MOR209/ES414, ES210, ES425, Otlertuzumab and 5E3. Its technology can produce monospecific and multispecific immunotherapeutic proteins that bind to various targets. The Company's marketed products are WinRho SDF (Rho(D) Immune Globulin Intravenous (Human)), HepaGam B (Hepatitis B Immune Globulin Intravenous (Human)) and VARIZIG (Varicella Zoster Immune Globulin (Human)).

Webull offers kinds of Aptevo Therapeutics Inc stock information, including NASDAQ:APVO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, APVO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading APVO stock methods without spending real money on the virtual paper trading platform.